Codiak BioSciences (Codiak BioSciences) Interest Expense : $-2.61 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Codiak BioSciences's interest expense for the three months ended in Sep. 2022 was $ -0.76 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.61 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Codiak BioSciences's Operating Income for the three months ended in Sep. 2022 was $ -16.89 Mil. Codiak BioSciences's Interest Expense for the three months ended in Sep. 2022 was $ -0.76 Mil. Codiak BioSciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Codiak BioSciences Interest Expense Historical Data

The historical data trend for Codiak BioSciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Interest Expense Chart

Codiak BioSciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Interest Expense

-0.30

-1.91

-2.70

Codiak BioSciences Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Interest Expense	Get a 7-Day Free Trial										-0.69	-0.61	-0.60	-0.65	-0.76

Codiak BioSciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.61 Mil.

Codiak BioSciences (OTCPK:CDAKQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Codiak BioSciences's Interest Expense for the three months ended in Sep. 2022 was $-0.76 Mil. Its Operating Income for the three months ended in Sep. 2022 was $-16.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2022 was $58.27 Mil.

Codiak BioSciences's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Codiak BioSciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Codiak BioSciences (Codiak BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140

Website

https://www.codiakbio.com

Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

Executives

Yalonda Howze	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan	officer: Chief Scientific Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams	director, officer: President & CEO	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann	director	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler	officer: Chief Medical Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp	10 percent owner	801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142